

Rev04
Update: Oct,19,2022

DATASHEET

Anti-Nivolumab Antibody(8G6G3D8), mAb, Mouse

Cat. No.: A01847

Overview

Specificity	The product is specific for Nivolumab. The antibody is recommended as a capture antibody in a pharmacokinetic (PK) bridging assay with detection antibody GenScript, A01848-40, Anti- Nivolumab Antibody (6G5H2E6), mAb, Mouse.
Host Species	Mouse
Immunogen	Nivolumab
Conjugate	Unconjugated

Applications

Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.


Application	Recommended Usage
ELISA	0.01-0.1 µg/ml

Properties

Form	Lyophilized
Storage Buffer	lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL.
Storage Instructions	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.

Purification	Protein A affinity column
Isotype	Mouse IgG1
Clonality	Monoclonal
Clone ID	8G6G3D8

Examples



Anti-Nivolumab Antibody (8G6G3D8), mAb, Mouse

(GenScript, A01847-40) binds with Nivolumab, while the antibody does not recognize human IgG Fc fragment (data not shown).

Coating antigen: Nivolumab, 1 µg/ml.

Anti-Nivolumab antibody (GenScript, A01847-40) dilution start from 1,000 ng/ml.

EC₅₀ = 2.72 ng/ml.

Background

Target Background : Nivolumab (Opdivo) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Nivolumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells. GenScript Anti-Nivolumab Antibody (8G6G3D8), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Nivolumab.

Synonyms : Mouse monoclonal to Opdivo

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.